

Date: 14.08.2024

To  
BSE Limited,  
Dept. of Corporate Services,  
Floor 25, PJ Towers, Dalal Street,  
Mumbai- 400001

Dear Sir/Madam,

**Scrip Code: 526445**

**Sub: Outcome of the Board Meeting.**

**Ref: Regulation 30 and Regulation 33 read with Schedule III of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015**

With reference to our intimation letter dated August 8, 2024 under Regulation 29 of SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015, we wish to inform that at the meeting of Board of Directors held today i.e., on Wednesday, August 14, 2024, the Directors have inter-alia, approved the Unaudited Financial Results (Standalone and Consolidated) with the Limited Review Report for the quarter ended June 30, 2024 pursuant to Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The statutory auditors have reviewed the financial results and given unmodified opinion.

We have attached herewith the copy of the unaudited financial results (standalone and consolidated) for the quarter ended June 30, 2024 along with the Limited Review Report for the said period.

The Board Meeting commenced at 02:00 P.M. and concluded at 07:25 P.M. The necessary arrangements are in place to publish the unaudited financial results in the newspapers. The said financial results will also be available on company's website [www.indrayani.com](http://www.indrayani.com) and also on BSE website [www.bseindia.com](http://www.bseindia.com).

Kindly take the same on records.

Thanking You,

Yours faithfully,  
For Indrayani Biotech Limited

V Santhanakrishnan  
Company Secretary and Compliance Officer

Encl: As above



**Limited Review Report on consolidated unaudited quarterly to date financial results of the company Pursuant to the regulation 33 of the SEBI (Listing Obligations and disclosure requirements) regulations, 2015**

To  
The Board of Directors  
**Indrayani Biotech Limited**

We have reviewed the accompanying Statement of Consolidated Financial Results of Indrayani Biotech Limited ("the Parent") and its subsidiaries (the Parent and its subsidiaries together referred to as "the Group") and its share of the net profit after tax and total comprehensive income / loss of its associates for the quarter ended **30<sup>th</sup> June, 2024** and for the period from 1<sup>st</sup> April 2024 to 30<sup>th</sup> June 2024 ("the Statement"), being submitted by the Parent pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended. Attention is drawn to the fact that the consolidated figures for the corresponding quarter ended 30<sup>th</sup> June, 2023 and corresponding period from 1<sup>st</sup> April 2023 to 30<sup>th</sup> June 2023 as reported in these financial results have been approved by the Parent's Board of Directors, but have not been subjected to audit/review.


This Statement, which is the responsibility of the Parent's Management and approved by the Parent's Board of Directors, has been compiled from the related consolidated financial statements which has been prepared in accordance with the Indian Accounting Standards prescribed under Section 133 of the Companies Act, 2013, read with the Companies (Indian Accounting Standards) Rules, 2015, as amended ("Ind AS"), and other accounting principles generally accepted in India. Our responsibility is to express an opinion on the Statement based on our review of such consolidated financial statements.

We conducted our review of the statement in accordance with the Standard on Review Engagement (SRE) 2410, 'Review of Interim Financial Information Performed by the Independent Auditor of the Entity', issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial results are free of material misstatements. A review is limited primarily to inquiries of Company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33 (8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, to the extent applicable.

The Statement includes the results of the entities mentioned in the Annexure – I, is presented in accordance with the requirements of Regulation 33 of the Listing Regulations, as amended;

Based on our review conducted and procedures performed as stated in paragraph above and based on the consideration of the reports of the management referred to in paragraph below, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements)



"SRI RANGA", New No.151, Mambalam High Road, T.Nagar, Chennai- 600 017.

Telefax: 2814 4763/64/65/66 Email: [audit@venkateshandco.com](mailto:audit@venkateshandco.com)



**VENKATESH & CO**  
Chartered Accountants

Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

We did not review the financial statement / financial information of **6 Subsidiaries and 3 step down subsidiaries** included in the consolidated unaudited financial results, whose interim financial information for the Period ended 30<sup>th</sup> June, 2024 reflects total revenues of **₹ 818.95 Lakhs**, total comprehensive profit / (loss) of **₹ (14.71 Lakhs)** for the period ended on that date as considered in the consolidated financial results.

This financial information have been reviewed by the Management and our opinion on the consolidated financial results, in so far as it relates to the amounts and disclosures included in respect of these subsidiaries, associates and joint ventures, is based solely on the reports of the Management and the procedures performed by us as stated in paragraph mentioned above.

**for Venkatesh & Co**

Chartered Accountants

FRN : 004636S

**CA Desikan G**

Partner

M No : 219101

UDIN: **24219101BKAPMY1156**

Chennai, 14<sup>th</sup> August 2024



**Annexure I to the Audit Report**

List of subsidiaries, associates and joint ventures included in the consolidated Quarterly Unaudited financial results:

S. No.	Name of the entity	Relationship
1	IBL Health Care Limited	Subsidiary
2	HSL Agri Solutions Limited	Subsidiary
3	HSL Prime Properties Private Limited	Subsidiary
4	Healthway India Private Limited	Step Down Subsidiary
5	IBL Thiruvannamalai LLP	Step Down Subsidiary
6	Dindigul Farm Products Limited*	Subsidiary
7	Matrix Boilers Private Limited	Subsidiary
8	IBL Investments Limited	Subsidiary
9	IBL Social Foundation	Subsidiary
10	Kniss Laboratories Private Limited	Step Down Subsidiary

**\*Consolidation Comprises of Financial results of Dindigul Farm Products Limited by the virtue of Control established over Board of Directors and decisions of management.**



INDRAYANI BIOTECH LIMITED  
CIN: L40100TN1992PLC129301

Regd. Office :

BLOCK 1, MODULE NO.33, 3rd FLOOR,SIDCO ELECTRONIC COMPLEX,  
THIRU VI KA INDUSTRIAL ESTATE,GUINDY CHENNAI - 600032

STATEMENT OF FINANCIAL RESULTS FOR THE QUARTER AND YEAR ENDED 30TH JUNE 2024

(Rs. in Lakhs, except EPS)

SN	PARTICULARS	CONSOLIDATED			
		Quarter Ended		Year Ended	
		30-Jun-24 Unaudited	31-Mar-24 Audited	30-Jun-23 Unaudited	31-Mar-24 Audited
1	<b>Income from Operations</b>				
	(a) Net Sales/Revenue from Operations	3,152.78	4,438.02	4,231.25	16,622.56
	(b) Other Income	4.43	103.33	0.87	121.49
	<b>Total Income from Operations</b>	<b>3,157.21</b>	<b>4,541.35</b>	<b>4,232.12</b>	<b>16,744.06</b>
2	<b>Expenses</b>				
	(a) Cost of Materials consumed	1,667.00	2,609.73	2,815.54	10,321.76
	(b) Changes in inventories of finished goods, work-in-progress and stock-in-trade	91.33	(608.51)	-	(608.51)
	(c) Employee benefits expenses	571.95	846.13	538.52	2,392.94
	(d) Finance Costs	224.87	551.30	202.80	988.25
	(e) Depreciation and amortisation expense	82.74	95.96	89.85	380.06
	(f) Other expenses	424.85	573.45	623.73	2,172.11
	<b>Total Expenses</b>	<b>3,062.75</b>	<b>4,068.06</b>	<b>4,270.44</b>	<b>15,646.62</b>
3	<b>Total profit / (Loss) before exceptional items and tax</b>	<b>94.46</b>	<b>473.29</b>	<b>(38.33)</b>	<b>1,097.44</b>
4	<b>Exceptional Items</b>				
	Add: Share of Profit In Associates		-		-
	Less: Written off CWIP		-		-
5	<b>Total profit / (Loss) before tax</b>	<b>94.46</b>	<b>473.29</b>	<b>(38.33)</b>	<b>1,097.44</b>
6	<b>Tax Expenses</b>				
	Current Tax	9.45		6.23	61.85
	Deferred Tax		-	-	(6.66)
	<b>Total Tax Expenses</b>	<b>9.45</b>	<b>-</b>	<b>6.23</b>	<b>55.19</b>
7	<b>Net Profit Loss for the period from continuing operations</b>	<b>85.01</b>	<b>473.29</b>	<b>(44.56)</b>	<b>1,042.25</b>
8	<b>Profit (loss) from discontinued operations before tax</b>				
9	<b>Tax expense of discontinued operations</b>				
10	<b>Net profit (loss) from discontinued operation after tax</b>				
11	Share of profit (loss) of associates and joint ventures accounted for using equity method		-	-	
12	<b>Total profit (loss) for period</b>	<b>85.01</b>	<b>473.29</b>	<b>(44.56)</b>	<b>1,042.25</b>
13	<b>Other comprehensive income net of taxes</b>				
14	<b>Total Comprehensive Income for the period</b>				
	<b>Total profit or loss, attributable to</b>				
	<b>Profit or loss, attributable to owners of parent</b>				
	Total profit or loss, attributable to non-controlling interests				
14	<b>Total Comprehensive income for the period attributable to</b>				
	Comprehensive income for the period attributable to owners of parent	43.90	386.90	(21.20)	636.49
	Total comprehensive income for the period attributable to Non-controlling Interests	41.11	86.40	(23.36)	405.79
15	<b>Paid-up equity share capital (Face value Rs.10 each)</b>	<b>4,553.63</b>	<b>4,553.63</b>	<b>3,422.72</b>	<b>4,553.63</b>
16	<b>Earnings per share</b>				
	Basic earnings (loss) per share *(not annualised) (in Rs.)	0.10*	0.58*	0.06*	1.40
	Diluted earnings (loss) per share *(not annualised) (in Rs.)	0.10*	0.58*	0.09*	1.40

Notes:

1.The above Consolidated financial results were reviewed and recommended by the Audit Committee and approved by the Board of Directors Directors at their meeting held on 14th August 2024 and have been subjected to review by the Statutory Auditors of the company. The above results have been prepared in accordance with the Indian Accounting Standards-(Ind AS) as prescribed under Section 133 of the Companies Act 2013, read with Rule 3 of the Companies (Indian Accounting Standards) Rules, 2015 and Companies (Indian Accounting Standards) Amendment Rules, 2016.

2.The financial results are being forwarded to the Bombay Stock Exchange & also available on the company website (www.indrayani.com).

3.The figures for the quarter ended 31 March 2024 are the balancing figures between the audited figures in respect of the financial year ended 31 March 2024 and published year to date figures for nine months ended 31 December 2023, which were subjected to limited review by the statutory auditors.

4. Previous period figures have been regrouped wherever necessary.

5. There is no investor complaint received during the quarter.

For Indrayani Biotech Limited

*[Signature]*

Swaminathan  
Whole-time Director (DIN: 02481041)



Date : 14/08/2024  
Place : Chennai



**VENKATESH & CO**  
Chartered Accountants

**Limited Review Report on Quarterly Financial Results of Indrayani Biotech Limited pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015**

To  
The Board of Directors,  
**Indrayani Biotech Limited**

We have reviewed the accompanying statement of unaudited standalone financial results of **Indrayani Biotech Limited** ('the Company') for the quarter ended 30<sup>th</sup> June 2024. This statement, is the responsibility of the Company's Management and has been approved by the Board of Directors, has been prepared in accordance with the applicable Indian Accounting Standards (Ind AS) specified under Section 133 of the Companies Act, 2013. Our Responsibility is to issue a report on these financial statements based on our review.

We conducted our review of the statement in accordance with the Standard on Review Engagement (SRE) 2410, 'Review of Interim Financial Information Performed by the Independent Auditor of the Entity', issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial results are free of material misstatements. A review is limited primarily to inquiries of Company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable Indian Accounting Standards ('Ind AS') prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

**for Venkatesh & Co**  
Chartered Accountants  
FRN : 004636S


**CA Desikan G**  
Partner  
M No : 219101  
UDIN: **24219101BKAPMX7717**  
Chennai, 14<sup>th</sup> Aug 2024



INDRAYANI BIOTECH LIMITED  
CIN: L40100TN1992PLC129301

Regd. Office :

BLOCK 1, MODULE NO.33, 3rd FLOOR, SIDCO ELECTRONIC COMPLEX,  
THIRU VI KA INDUSTRIAL ESTATE, GUINDY CHENNAI - 600032

STATEMENT OF FINANCIAL RESULTS FOR THE QUARTER AND YEAR ENDED 30TH JUNE 2024  
(Rs. in Lakhs, except EPS)

SN	PARTICULARS	STANDALONE			
		Quarter Ended		Year Ended	
		30-Jun-24	31-Mar-24	30-Jun-23	31-Mar-24
		Unaudited	Audited	Unaudited	Audited
1	<b>Income from Operations</b>				
	(a) Net Sales/Revenue from Operations	1,079.09	1,579.93	1,681.86	6,232.34
	(b) Other Income	102.60	344.58	0.54	361.88
	<b>Total Income from Operations</b>	<b>1,181.69</b>	<b>1,924.51</b>	<b>1,682.40</b>	<b>6,594.22</b>
2	<b>Expenses</b>				
	(a) Cost of Materials consumed	484.52	762.38	951.99	3,515.38
	(b) Changes in inventories of finished goods, work-in-progress and stock-in-trade	-	-	-	-
	(c) Employee benefits expenses	403.58	490.45	361.52	1,569.08
	(d) Finance Costs	151.63	247.25	95.84	482.76
	(e) Depreciation and amortisation expense	31.98	35.46	36.08	144.76
	(f) Other expenses	92.93	226.57	165.32	581.31
	<b>Total Expenses</b>	<b>1,164.64</b>	<b>1,762.11</b>	<b>1,610.75</b>	<b>6,293.31</b>
3	<b>Total profit / (Loss) before exceptional items and tax</b>	<b>17.05</b>	<b>162.40</b>	<b>71.65</b>	<b>300.91</b>
4	<b>Exceptional Items</b>				
	Add: Share of Profit In Associates	-	-	-	-
	Less: Written off CWIP	-	-	-	-
5	<b>Total profit / (Loss) before tax</b>	<b>17.05</b>	<b>162.40</b>	<b>71.65</b>	<b>300.91</b>
6	<b>Tax Expenses</b>				
	Current Tax	4.33	54.17	-	54.17
	Deferred Tax	-	101.00	-	101.00
	<b>Total Tax Expenses</b>	<b>4.33</b>	<b>155.17</b>	<b>-</b>	<b>155.17</b>
7	<b>Net Profit Loss for the period from continuing operations</b>	<b>12.72</b>	<b>7.23</b>	<b>71.65</b>	<b>145.74</b>
8	<b>Profit (loss) from discontinued operations before tax</b>				
9	<b>Tax expense of discontinued operations</b>				
10	<b>Net profit (loss) from discontinued operation after tax</b>				
11	<b>Share of profit (loss) of associates and joint ventures accounted for using equity method</b>				
12	<b>Total profit (loss) for period</b>	<b>12.72</b>	<b>7.23</b>	<b>71.65</b>	<b>145.74</b>
13	<b>Paid-up equity share capital (Face value Rs.10 each)</b>	<b>4,553.63</b>	<b>4,553.63</b>	<b>3,422.72</b>	<b>4,553.63</b>
14	<b>Earnings per share</b>				
	Basic earnings (loss) per share *(not annualised) (in Rs.)	0.03*	0.08*	0.21*	0.32
	Diluted earnings (loss) per share *(not annualised) (in Rs.)	0.03*	0.08*	0.20*	0.32

Notes:

- The above Standalone financial results were reviewed and recommended by the Audit Committee and approved by the Board of Directors Directors at their meeting held on 14th August 2024 and have been subjected to review by the Statutory Auditors of the company. The above results have been prepared in accordance with the Indian Accounting Standards-(Ind AS) as prescribed under Section 133 of the Companies Act 2013, read with Rule 3 of the Companies (Indian Accounting Standards) Rules, 2015 and Companies (Indian Accounting Standards) Amendment Rules, 2016.
- The financial results are being forwarded to the Bombay Stock Exchange & also available on the company website (www.indrayani.com).
- The figures for the quarter ended 31 March 2024 are the balancing figures between the audited figures in respect of the financial year ended 31 March 2024 and published year to date figures for nine months ended 31 December 2023, which were subjected to limited review by the statutory auditors.
- Previous period figures have been regrouped wherever necessary.
- There is no investor complaint received during the quarter.

Date : 14/08/2024  
Place : Chennai

For Indrayani Biotech Limited

Swaminathan  
Whole-time Director (DIN: 02481041)

